This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): BMS-354825, NSC-732517, dasatinib
Description: Sprycel is a rationally designed oral investigational agent that inhibits five tyrosine kinase proteins including BCR/ABL and SRC proteins.
In vitro studies have shown that BMS-354825 is 100-fold more potent than Gleevec (imatinib) and has demonstrated efficacy against 14 of 15 imatinib resistant BCR-ABL mutants.
In April 2009, Bristol-Myers Squibb and Otsuka Pharmaceutical have established an oncology collaboration for SPRYCEL and IXEMPRA.
Beginning in 2010, Bristol-Myers Squibb and Otsuka will collaborate on two oncology assets SPRYCEL and IXEMPRA as follows:
- Otsuka will share in commercial expenses for the U.S., Europe and Japan and co-promote SPRYCEL with Bristol-Myers Squibb in the U.S., Japan and major EU markets;
- Bristol-Myers Squibb will pay Otsuka a collaboration fee on aggregate annual net sales of SPRYCEL and IXEMPRA beginning in 2010 on a regressive tiering basis through 2020.
Partners: Otsuka Holdings Co., Ltd.
Pink Sheet Sprycel FDA Reviewers
Pink Sheet Sprycel Clinical Development
Additional information available to subscribers only: